BIO CEO Advisory Committee
 |
Erin Brubaker As the Head of Alliance Management at GlaxoSmithKline (GSK), Erin and her team are responsible for centrally managing complex, highly strategic, late-phase and high-value alliances for GSK’s Research & Development (R&D) organization. In addition, Erin leads the Alliance Management Centre of Excellence, which works to ensure there is consistency of practices, shared learnings, and collaboration between professionals across GSK who work closely with external partners, and the central Alliance Management team in Worldwide Business Development (WWBD). Prior to joining WWBD, Erin held several Global and US roles at GSK with increasing levels of responsibility for bringing the voice of the customers into the development of new medicines and linking the science behind internal assets and business development opportunities to the value proposition across a therapeutically diverse portfolio. Erin’s leadership is evidenced by her selection as: “Top Marketing 100” by Advertising Age magazine (October 2001) and “Rising Star” by the Healthcare Businesswomen’s Association (May 2007), as well as by her nomination for and participation in the LEADERSHIP Philadelphia class of 2009. |
 |
John Chambers John Chambers, a Managing Director and Head of Healthcare Investment Banking group, joined Roth Capital Partners in December 2009. Chambers was formerly the head of Merriman Curhan Ford’s Heath Care and investment banking team. Prior to joining Merriman, Chambers was co-head of investment banking at Rodman & Renshaw. He has also held senior-level health care and biotechnology banking positions at SG Cowen, Lehman Brothers, UBS and Salomon Smith Barney. Chambers has executed a significant number of banking transactions, strategic transactions and restructurings across all health care sectors. Chambers earned his M.B.A. from Columbia Business School and his B.S. in mechanical engineering from Union College. |
 |
Annette Grimaldi Annette joined BMO Capital Markets in December 2009 as a Managing Director in the Healthcare Group with responsibility for its Life Sciences practice. Prior to joining BMO Capital Markets, Annette spent four years at Jefferies & Company where she was a Managing Director responsible for the Life Sciences investment banking effort. Previous to Jefferies, Annette spent ten years as a Managing Director and senior member of SG Cowen’s healthcare investment banking team. Annette began her investment banking career at Goldman, Sachs & co. where she spent eight years working in the healthcare group and as part of the Japan desk. Annette has an MBA with honors from the University of Pennsylvania’s Wharton School of Business and an MA in International Studies from the University of Pennsylvania Lauder Institute. Annette graduated Phi Beta Kappa with a Bachelor of Science from Georgetown University’s School of Foreign Service. |
 |
Michael Hay Michael has been with Sagient for over seven years and has over 11 years of financial markets experience. He manages the BioMedTracker analyst team and serves as Vice President at Sagient. He is also responsible for product development, corporate planning and sales and marketing. Michael has consulted numerous top tier pharmaceutical companies on strategic decisions as well as worked closely with top healthcare investment firms providing insight on investment and trading decisions. Michael's financial markets career began at Thomson Financial in 2000. He reached the position of Manager, Capital Markets Intelligence and was directly responsible for corporate client relationships within the Technology sector. At Thomson he consulted senior management regarding shareholder composition, financial markets and competitive positioning. Michael received a Bachelor of Science degree in Finance from University of Colorado, Boulder. |
 |
Michael G. King, Jr. Michael G. King, Jr., is a Managing Director and Senior Biotechnology Analyst. Mr. King has over 17 years of experience as a leading biotechnology equity research analyst, consistently ranking at the top of Institutional Investor magazine's annual sell-side research survey in addition to being named that publication's "Home Run Hitter" in 2000. Most recently, Mr. King served as Senior Vice President of Corporate Development and Communication at ZIOPHARM Oncology (NASDAQ: ZIOP), a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer therapeutics. Prior to joining ZIOPHARM, Mr. King was a Managing Director and Senior Biotechnology Analyst at Wedbush Securities. Prior to that, Mr. King was a Managing Director and Senior Biotechnology Analyst at Merriman Curhan Ford with other prior positions at leading firms including Dillon Read, Vector Securities International, Robertson Stephens, Banc of America Securities and Rodman & Renshaw, where he was Director of Research. Mr. King began his career in finance in sales at Kidder Peabody. |
 |
Peter Kolchinksky, PhD Dr. Kolchinsky is a co-founder and General Partner of RA Capital Management, which has been investing in healthcare companies since 2002. He is a member of the National Academies Board on Global Science and Technology, authored an e-book titled “The Entrepreneur’s Guide to a Biotech Startup”, and serves as an advisor to startup companies and non-profits. Peter received his undergraduate degree in Biology from Cornell University and a Ph.D. in Virology from Harvard University, where he conducted research at Dana-Farber Cancer Institute on the entry mechanism of Human Immunodeficiency Virus (HIV). |
 |
James S.J. Manuso, PhD, MBA
James S.J. Manuso serves as chairman and chief executive officer of Astex Pharmaceuticals. He served as SuperGen chairman, president and CEO from January 2004 to July 2011, as chief executive officer-elect from September 2003 to December 2003 and as a director since February 2001. He is co-founder and immediate past president and chief executive officer of Galenica Pharmaceuticals, Inc. Dr. Manuso co-founded and was general partner of PrimeTech Partners, a biotechnology venture management partnership, from 1998 to 2002, and co-founder and managing general partner of The Channel Group LLC, an international life sciences corporate advisory firm. He was also president of Manuso, Alexander & Associates, Inc., management consultants and financial advisors to pharmaceutical and biotechnology companies. Dr. Manuso was a vice president and director of Health Care Planning and Development for The Equitable Companies (now Group Axa), where he also served as an acting medical director. He currently serves on the boards of Novelos Therapeutics, Inc. (NVLT:OB) and privately-held KineMed, Inc. Previously, he served on the boards of Merrion Pharmaceuticals Ltd. (MERR:IEX; Dublin, Ireland), Inflazyme Pharmaceuticals, Inc., Symbiontics, Inc. (subsequently sold to BioMarin as ZyStor Therapeutics, Inc.), Quark Pharmaceuticals, Inc., Galenica Pharmaceuticals, Inc., and Supratek Pharma, Inc. Dr. Manuso earned a B.A. with Honors in Economics and Chemistry from New York University, a Ph.D. in Experimental Psychophysiology from the Graduate Faculty of The New School University, a Certificate in Health Systems Management from Harvard Business School, and an Executive M.B.A. from Columbia Business School. Dr. Manuso is the author of over 30 chapters, articles and books on topics including health care cost containment and biotechnology company management. He has taught and lectured at Columbia, New York University, Georgetown, Polytechnic University, Waseda University (Japan) and elsewhere. He has delivered invited addresses at meetings of the American Management Association, the American Medical Association, the Securities Industry Association, the Biotechnology Industry Organization, and many other professional associations. Dr. Manuso serves on the Board of Directors of the Biotechnology Industry Organization (BIO) and its Health Section Governing Board. He previously served as vice president and a member of the Board of Trustees of the Greater San Francisco Bay Area Leukemia & Lymphoma Society. |
 |
Evan McCulloch Evan McCulloch is a vice president, portfolio manager and analyst for Franklin Equity Group. Mr. McCulloch is the lead portfolio manager of Franklin Biotechnology Discovery Fund. He is also the health care sector team leader. Mr. McCulloch specializes in research analysis of biotechnology and emerging pharmaceutical companies, with a therapeutic focus on infectious diseases, ophthalmology, pulmonology, cardiovascular disease, gastroenterology and the central nervous system. Prior research coverage includes the pharmaceutical, medical technology and healthcare service sectors. Mr. McCulloch joined Franklin Templeton Investments in 1992. He earned his B.A. in economics from the University of California at Berkeley. He is a Chartered Financial Analyst (CFA) Charterholder, and a member of the CFA Institute and the Security Analysts of San Francisco (SASF). |
 |
Ronald C. Renauld Jr.
Ronald C. Renaud has served as the President and chief executive officer of Idenix Pharmaceuticals, Inc. since October 2010. Prior to this, Mr. Renaud has served as the chief financial officer of Idenix Pharmaceuticals, Inc. since June 2007 and additionally as Chief Business Officer since June 2010. Mr. Renaud brings a unique mix of skills to this role with his finance experience at public biotechnology companies and on Wall Street, as well as his science background. Prior to joining Idenix, Mr. Renaud served as chief financial officer of Keryx Biopharmaceuticals. In this role he was responsible for the strategic planning and development of the finance function to support the company’s growth and its late-stage product candidate development. Prior to his position at Keryx, he spent several years as a senior biotechnology equity analyst for leading investment banks including Bear Stearns, Schwab SoundView and JP Morgan. Additional industry experience includes Mr. Renaud's more than five years at Amgen Inc., where he held positions in clinical research, investor relations and finance. Mr. Renaud holds a Masters in Business Administration from the Marshall School of Business at the University of Southern California and a Bachelor of Arts from St. Anselm College in Manchester, NH. |
 |
Stephen Sands Stephen Sands is Vice Chairman of US Investment Banking and Global Co-Head of Lazard’s Healthcare Group. He has worked on behalf of both domestic and international life science clients in the biotech, specialty pharma and pharmaceutical sectors. Mr. Sands is also on the Board of Directors of Lazard Capital Markets and Lazard Alternative Investments Holdings LLC. Mr. Sands advised on some of the largest pharmaceutical and biotechnology transactions ever done including Pfizer’s acquisition of Pharmacia and Warner Lambert, UCB’s acquisition of Schwarz Pharma and Celltech, Hoechst on the formation of Aventis, Glaxo acquisition of Wellcome and Alcon on its sale to Novartis. Mr. Sands has also provided financial advice on some of the most challenging and creative transactions in the healthcare sector including the sale of Abraxis and APP Pharmaceuticals that incorporated significant contingent value rights, OSI in its contested transaction with Astellas and Endo on its strategy to diversify its business. In addition, he has assisted numerous companies to raise capital in the public markets. Prior to joining Lazard in 1994, Mr. Sands was a Partner in the health care practice of McKinsey & Company. While on sabbatical from McKinsey, Mr. Sands co-founded two biotechnology companies -- Enzytech and Opta Foods -- where he served as Vice President, Business Development and Treasurer. Prior to their sale Mr. Sands was a Director of National Imaging Associates, Inc (Magellan), and Isogen LLC (Monsanto). Mr. Sands has been the featured Keynote Speaker and participated as a panelist at numerous biotechnology conferences. He is a member of the Brookings/Gates Global Heath Innovative Financing Advisory Group, Rockefeller University Counsel, Washington University (St. Louis) Engineering Executive and Regional Counsels, and a Board member of the New York Hall of Science. Mr. Sands was also the New York Biotechnology Association’s (NYBA) inaugural recipient of The Cures Start Here® Business Leader of the Year Award 2008. Oberlin College, B.A. in Biology, Washington University in St. Louis, B.S. and M.S. in Chemical Engineering, New York University, M.B.A. in Finance. |
 |
Mark Schoenebaum
ISI’s Health Care Research Team, headed by Mark Schoenebaum, focuses on providing actionable investment ideas and proprietary research on Biotechnology, Pharmaceutical, and Specialty Pharmaceutical stocks. Mark has been conducting research on biotechnology companies for more than 10 years. Mark and his team provide clients with an investment edge through “data tidbits” and “on-the-fly” analysis in response to breaking news. They also provide "deep-dive" analyses on clinical, financial, and market data. The Health Care Research Team is available around the clock, conducts customized client projects, assists with corporate access, and accepts personal meetings. |
 |
Nathan P. Tinker, PhD Nathan Tinker has lead NYBA since 2007. In that role, he has driven the organization’s state and federal public policy initiatives, working to protect the New York life science industry and promote its benefits to the State, as well as the Association’s various industry development and support initiatives. Prior to joining NYBA, he was Executive Director at the Sabin Vaccine Institute Cancer Vaccine Consortium and Founder/Executive Vice President of the NanoBusiness Alliance, the national nanotechnology trade group. Nathan has also held senior management positions at Golin/Harris International, Niehaus Ryan Wong Public Relations, and the Antenna Group. He currently sits on the Board of Advisors for several organizations, including Physicians Interactive and Versilant Nanotechnologies. |
